verapamil has been researched along with Multiple Myeloma in 35 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical utility of anthracyclines like doxorubicin (DOX) and daunorubicin (DNR) for treatment of multiple myeloma (MM) is limited by the occurrence of multidrug resistance (MDR)." | 7.70 | Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. ( Bloem, AC; Lokhorst, HM; Roovers, DJ; van Vliet, M, 1999) |
| "The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs." | 5.28 | Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. ( Dalton, WS; Durie, BG; Grogan, TM; Meltzer, PS; Miller, TP; Salmon, SE; Scheper, RJ; Taylor, CW, 1989) |
| "A randomized trial of the combination of vincristine, doxorubicin, and dexamethasone (VAD) and VAD plus oral verapamil (VAD/v) in drug refractory multiple myeloma patients was performed by the Southwestern Oncology Group." | 5.08 | A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. ( Bonnet, JD; Crowley, JJ; Dalton, WS; Grogan, TM; Laufman, LR; Salmon, SS; Weiss, GR, 1995) |
| "Verapamil was evaluated as a chemosensitizer for reversing multidrug resistance in multiple myeloma both in vitro and in clinical trials." | 5.07 | Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. ( Dalton, WS; Grogan, TM; Lehnert, M; Miller, TP; Plezia, P; Roe, DJ; Salmon, SE, 1991) |
| "The proteasome inhibitor bortezomib is clinically approved for the treatment of multiple myeloma." | 3.76 | Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. ( Frey, B; Gaipl, US; Lang, VR; Meister, S; Schett, G; Schlötzer-Schrehardt, U; Voll, RE, 2010) |
| "The clinical utility of anthracyclines like doxorubicin (DOX) and daunorubicin (DNR) for treatment of multiple myeloma (MM) is limited by the occurrence of multidrug resistance (MDR)." | 3.70 | Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. ( Bloem, AC; Lokhorst, HM; Roovers, DJ; van Vliet, M, 1999) |
| " To this end, the human multiple myeloma cell line RPMI 8226 (8226/S) was selected with either doxorubicin, verapamil or doxorubicin plus verapamil." | 3.69 | Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. ( Dalton, WS; Foley, NE; Futscher, BW; Gleason-Guzman, MC; Meltzer, PS; Sullivan, DM, 1996) |
| "Verapamil reversed resistance to doxorubicin in a human multiple myeloma cell line selected for multiple drug resistance." | 3.67 | Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. ( Alberts, DS; Bellamy, WT; Dalton, WS; Dorr, RT; Gleason, MC; Kailey, JM; McCloskey, TM, 1988) |
| "Verapamil was without influence on any parameters in this study." | 2.68 | A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. ( Cunningham, D; Gore, M; Kulkarni, S; Mehta, J; Middleton, G; Milan, S; Millar, B; Powles, R; Raje, N; Raymond, J; Singhal, S; Treleaven, J; Viner, C, 1997) |
| "When verapamil was added to the treatment regimen of those animals bearing the 8226/C1N xenografts, there was a 179% increase in their life span (P < 0." | 1.29 | Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts. ( Bellamy, WT; Dalton, WS; Grogan, TM; Huizenga, E; Odeleye, A; Weinstein, RS, 1995) |
| "The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs." | 1.28 | Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. ( Dalton, WS; Durie, BG; Grogan, TM; Meltzer, PS; Miller, TP; Salmon, SE; Scheper, RJ; Taylor, CW, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (20.00) | 18.7374 |
| 1990's | 20 (57.14) | 18.2507 |
| 2000's | 4 (11.43) | 29.6817 |
| 2010's | 4 (11.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsubaki, M | 2 |
| Komai, M | 2 |
| Itoh, T | 2 |
| Imano, M | 2 |
| Sakamoto, K | 1 |
| Shimaoka, H | 1 |
| Takeda, T | 1 |
| Ogawa, N | 1 |
| Mashimo, K | 1 |
| Fujiwara, D | 1 |
| Mukai, J | 1 |
| Sakaguchi, K | 1 |
| Satou, T | 2 |
| Nishida, S | 2 |
| Meister, S | 1 |
| Frey, B | 1 |
| Lang, VR | 1 |
| Gaipl, US | 1 |
| Schett, G | 1 |
| Schlötzer-Schrehardt, U | 1 |
| Voll, RE | 1 |
| Iijima, M | 1 |
| Momose, I | 1 |
| Ikeda, D | 1 |
| Nishinobo, M | 1 |
| Yamashita, M | 1 |
| Yanae, M | 1 |
| Yamazoe, Y | 1 |
| Schwarzenbach, H | 1 |
| Raaijmakers, HG | 1 |
| Van Den Bosch, G | 1 |
| Boezeman, J | 1 |
| De Witte, T | 1 |
| Raymakers, RA | 1 |
| Wesierska-Gadek, J | 1 |
| Biscardi, M | 1 |
| Teodori, E | 1 |
| Caporale, R | 1 |
| Budriesi, R | 1 |
| Balestri, F | 1 |
| Scappini, B | 1 |
| Gavazzi, S | 1 |
| Grossi, A | 1 |
| Marie, JP | 1 |
| Zhou, D | 1 |
| Delmer, A | 1 |
| Zittoun, R | 1 |
| Dalton, WS | 12 |
| Crowley, JJ | 1 |
| Salmon, SS | 1 |
| Grogan, TM | 5 |
| Laufman, LR | 1 |
| Weiss, GR | 1 |
| Bonnet, JD | 1 |
| Lehnert, M | 3 |
| Emerson, S | 1 |
| de Giuli, R | 1 |
| Salmon, SE | 3 |
| Adam, Z | 1 |
| Vorlícek, J | 1 |
| Abbaszadegan, MR | 2 |
| Foley, NE | 2 |
| Gleason-Guzman, MC | 2 |
| Futscher, BW | 2 |
| Meltzer, PS | 2 |
| Sullivan, DM | 1 |
| Cress, AE | 1 |
| Bellamy, WT | 4 |
| Wyler, B | 1 |
| Shao, Y | 1 |
| Schneider, E | 1 |
| Cianfriglia, M | 1 |
| Scheper, RJ | 2 |
| Frey, BM | 1 |
| Gieseler, F | 1 |
| Schmid, L | 1 |
| Twentyman, PR | 1 |
| Raje, N | 2 |
| Powles, R | 2 |
| Kulkarni, S | 2 |
| Milan, S | 2 |
| Middleton, G | 1 |
| Singhal, S | 2 |
| Mehta, J | 2 |
| Millar, B | 2 |
| Viner, C | 2 |
| Raymond, J | 1 |
| Treleaven, J | 2 |
| Cunningham, D | 2 |
| Gore, M | 2 |
| Shepherd, V | 1 |
| Sokołowska, B | 1 |
| Dmoszyńska, A | 1 |
| Walter-Croneck, A | 1 |
| Wojtaszko, M | 1 |
| Odeleye, A | 1 |
| Huizenga, E | 1 |
| Weinstein, RS | 1 |
| Roovers, DJ | 1 |
| van Vliet, M | 1 |
| Bloem, AC | 1 |
| Lokhorst, HM | 1 |
| Post, J | 1 |
| Vooijs, WC | 1 |
| Bast, BJ | 1 |
| De Gast, GC | 1 |
| Plezia, P | 1 |
| Roe, DJ | 1 |
| Miller, TP | 3 |
| Solary, E | 2 |
| Bidan, JM | 2 |
| Calvo, F | 1 |
| Chauffert, B | 2 |
| Caillot, D | 2 |
| Mugneret, F | 1 |
| Gauville, C | 1 |
| Tsuruo, T | 1 |
| Carli, PM | 1 |
| Guy, H | 2 |
| Velay, I | 1 |
| Dumas, M | 1 |
| Grogan, T | 1 |
| Dalton, W | 1 |
| Rybski, J | 1 |
| Spier, C | 1 |
| Meltzer, P | 1 |
| Richter, L | 1 |
| Gleason, M | 1 |
| Pindur, J | 1 |
| Cline, A | 1 |
| Scheper, R | 1 |
| Mertens, M | 1 |
| Thomas, L | 1 |
| vd Lelie, J | 1 |
| Gottesman, MM | 1 |
| Pastan, I | 1 |
| Durie, BG | 2 |
| Taylor, CW | 1 |
| Trümper, LH | 1 |
| Ho, AD | 1 |
| Wulf, G | 1 |
| Hunstein, W | 1 |
| Millar, BC | 1 |
| Bell, JB | 1 |
| Maitland, JA | 1 |
| Zuiable, A | 1 |
| Gore, ME | 1 |
| Selby, PJ | 1 |
| McElwain, TJ | 1 |
| Dorr, RT | 2 |
| Alberts, DS | 2 |
| Kailey, JM | 1 |
| Gleason, MC | 1 |
| McCloskey, TM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for verapamil and Multiple Myeloma
| Article | Year |
|---|---|
[Trials of modulating the MDR1 phenotype in malignant hemopathies].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Dexamethasone; Doxorubicin; D | 1994 |
[Resistance to cytostatic agents in patients with refractory multiple myeloma and possible ways to control it].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cy | 1993 |
The role of P-glycoprotein in drug-resistant hematologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpor | 1991 |
5 trials available for verapamil and Multiple Myeloma
| Article | Year |
|---|---|
[Trials of modulating the MDR1 phenotype in malignant hemopathies].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Dexamethasone; Doxorubicin; D | 1994 |
A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Casse | 1995 |
A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosp | 1997 |
Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood C | 1997 |
Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1991 |
28 other studies available for verapamil and Multiple Myeloma
| Article | Year |
|---|---|
By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Sub | 2014 |
Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calcium Channel Blockers; | 2010 |
Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2010 |
Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding | 2012 |
Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; DNA, Complementary; | 2002 |
Single-cell image analysis to assess ABC-transporter-mediated efflux in highly purified hematopoietic progenitors.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, CD34; ATP Binding Cassette Trans | 2002 |
Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transpo | 2005 |
Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Antibiotics, Antineoplastic; Aorta; | 2006 |
In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cyclosporine; Drug Resist | 1993 |
Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; DNA Topoisomerase | 1996 |
Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Nucleus; DNA Topoisomerases, Type II; | 1996 |
Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport | 1996 |
Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, M | 1997 |
[The influence of verapamil on platelet function in patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1997 |
Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Cha | 1995 |
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, M | 1999 |
Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1999 |
P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance; Humans; Leuke | 1991 |
Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM.
Topics: Doxorubicin; Drug Resistance; Feasibility Studies; Humans; Leukemia; Leukemia, Myeloid, Acute; Multi | 1991 |
Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies.
Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cell Sur | 1990 |
Lack of reversal with verapamil of drug resistance in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Humans; Multiple Myeloma; Verapamil | 1990 |
Clinical trials of agents that reverse multidrug-resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1989 |
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter | 1989 |
Addition of verapamil to overcome drug resistance in multiple myeloma: preliminary clinical observations in 10 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Drug Resistance; F | 1989 |
In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Survival; Colony-Forming Units Assay; | 1989 |
Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.
Topics: Cell Survival; DNA Damage; DNA, Neoplasm; Doxorubicin; Drug Resistance; Humans; Multiple Myeloma; Tu | 1988 |
Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.
Topics: Cell Survival; DNA Damage; Doxorubicin; Drug Resistance; Humans; Multiple Myeloma; Tumor Cells, Cult | 1988 |
Reversal of drug-resistance in multiple myeloma with verapamil.
Topics: Adult; Cell Line; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Ass | 1988 |